A regulatory loop among CD276, miR-29c-3p, and Myc exists in cancer cells against natural killer cell cytotoxicity

A review of cancer immunotherapy toxicity

(2020) Lucy Boyce Kennedy et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Immune checkpoint signaling and cancer immunotherapy

(2020) Xing He et al.   CELL RESEARCH

Systematic Review of miR-29 in Cancer

(2019) Jason J. Kwon et al.   Molecular Therapy-Oncolytics

B7H3 regulates differentiation and serves as a potential biomarker and theranostic target for human glioblastoma

(2019) Jingwen Zhang et al.   LABORATORY INVESTIGATION

Advances in cancer immunotherapy 2019 – latest trends

(2019) Stephan Kruger et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Role of MYC-miR-29-B7-H3 in Medulloblastoma Growth and Angiogenesis

(2019) Ian J. Purvis et al.   Journal of Clinical Medicine

miR-29a is repressed by MYC in pancreatic cancer and its restoration drives tumor suppressive effects via downregulation of LOXL2

(2019) Shatovisha Dey et al.   MOLECULAR CANCER RESEARCH

IGF-1-enhanced miR-513a-5p signaling desensitizes glioma cells to temozolomide by targeting the NEDD4L-inhibited Wnt/β-catenin pathway

(2019) Ku-Chung Chen et al.   PLoS One

B7-H3 in tumors: friend or foe for tumor immunity?

(2018) Gen Li et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

MYC: Master Regulator of Immune Privilege

(2017) Stephanie C. Casey et al.   TRENDS IN IMMUNOLOGY

Cancer immunotherapy: the beginning of the end of cancer?

(2016) Sofia Farkona et al.   BMC Medicine

Combination cancer immunotherapy and new immunomodulatory targets

(2015) Kathleen M. Mahoney et al.   NATURE REVIEWS DRUG DISCOVERY

Glycoprotein B7-H3 overexpression and aberrant glycosylation in oral cancer and immune response

(2015) Jung-Tsu Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

B7-H3 silencing by RNAi inhibits tumor progression and enhances chemosensitivity in U937 cells

(2015) Wei Zhang et al.   OncoTargets and Therapy

Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c

(2014) M K Nygren et al.   BRITISH JOURNAL OF CANCER

Immune Escape Mechanisms as a Guide for Cancer Immunotherapy

(2014) G. L. Beatty et al.   CLINICAL CANCER RESEARCH

c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT

(2014) D-W Wu et al.   ONCOGENE

B7-H3 Associated with Tumor Progression and Epigenetic Regulatory Activity in Cutaneous Melanoma

(2013) Jinhua Wang et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas

(2012) Xinwei Zhang et al.   CANCER CELL

MicroRNA miR-29 Modulates Expression of Immunoinhibitory Molecule B7-H3: Potential Implications for Immune Based Therapy of Human Solid Tumors

(2009) H. Xu et al.   CANCER RESEARCH

The Immunoregulatory Protein Human B7H3 is a Tumor-Associated Antigen that Regulates Tumor Cell Migration and Invasion

(2008) Yih-Wen Chen et al.   CURRENT CANCER DRUG TARGETS

microRNAs and the immune response

(2008) Mark A. Lindsay   TRENDS IN IMMUNOLOGY